Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
about
Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fictionOptimizing the use of thiopurines in inflammatory bowel diseaseUse of thiopurines in inflammatory bowel disease: Safety issues.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Review article: acute severe ulcerative colitis - evidence-based consensus statements.Allopurinol reduces antigen-specific and polyclonal activation of human T cells.Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.Immunosuppressive and biologic therapy for ulcerative colitis.Review article: strategies for the management of chronic unremitting ulcerative colitis.Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.Positioning therapy for Crohn's disease.The role of thiopurine metabolite monitoring in inflammatory bowel disease.The role and advances of immunomodulator therapy for inflammatory bowel disease.A practical guide to the use of thiopurines in oral medicine.Drug Management in the Elderly IBD Patient.Toxicity and response to thiopurines in patients with inflammatory bowel disease.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Low dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital.Thiopurine metabolite testing in inflammatory bowel disease.Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Successful Pregnancies with Thiopurine-Allopurinol Co-Therapy for Inflammatory Bowel Disease.Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone.Commentary: Individual vs. weight-based dosing of azathioprine in Crohn's disease.Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.Editorial: can we get more clinical benefit from thiopurine metabolite testing?Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD.Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot eczema treated with azathioprine.Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease.Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
P2860
Q27023839-F07A697A-C59D-4CD4-9BD7-D0DBB2E50CF7Q28082687-DE927489-F76B-4AF1-942D-235FCFF76975Q33621267-88F1B6CB-B2EA-44FA-956C-53BA37A452BEQ33654733-F7F05A77-2A7A-415C-B0A5-F1D0418BBC80Q34528270-EACF0297-114F-4A4E-9356-BF659C5E6094Q36250232-F584E365-ED16-4FC9-86A4-11058193B865Q37570037-35D1755E-0DFB-4032-BA16-B5C7A16AE7A7Q38060831-8E31E369-A922-443B-8211-94121B8F59BAQ38110317-EB701191-5BE5-4AA9-8D70-40F60978FEDFQ38179509-3BF52678-DF94-4875-BFF4-609259636B57Q38195146-874A473F-00A5-44BE-87AA-C4BA9A85A8E7Q38200554-1793E916-91B2-4E08-BF94-655CDD36E43DQ38200692-F418EC47-528C-400B-B82B-8BD650D7C676Q38237701-531F8BC0-98DF-4945-9AC2-802D0B8203D1Q38295916-FF8076F8-F7EB-479C-AC22-AC17D07728C9Q38330651-40EAACE1-9D60-48D4-B6E1-0306DC3532FDQ38443981-0E8C4ED6-9519-4FD6-BC11-DD91DE1911BFQ38501680-C7EFE0ED-741B-432F-88F4-C9ECF49EFC3CQ38563075-2A0370AF-3192-4555-977F-2110B56020D5Q38608975-BCA5C10C-9D2A-4CC0-ADB8-F4197A5D943EQ38618602-6C3FBB7A-BBE6-46C0-AA94-FD5A7FFFF0EEQ38994349-95697048-5520-4FBA-B4EA-664CF40E0F3AQ39435409-0C17DFF3-C9F3-4784-85DE-DDC060CBDC3FQ40978974-152406E8-7B12-42F6-A2C0-3079667F35B8Q42257605-B04709E8-6128-4C36-8C85-1442CB6B9A98Q47187671-ABFF994B-1574-4539-A010-03443530ED02Q47652468-7018B244-D375-4F45-A3C0-A24E9DED9BAAQ48191847-3A2BB913-DEF3-4479-A9E3-F659444A5499Q48223472-8F0EBAFD-6A89-4B1D-BE0B-BE48309C3DF0Q49292225-1C61615D-4116-4E24-9C87-E2D1229AF8D1Q50072029-DBFD07A6-6D0A-416F-8B47-499736B2EA97Q50217361-3977A397-2F4D-4BEE-89E7-82C648F5431AQ55162386-C14B31F0-22C2-497D-B32D-3BA28C0221BCQ57817595-108615F8-CD72-4B4A-9C5A-6A4861445029
P2860
Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Optimising outcome on thiopuri ...... o-prescription of allopurinol.
@en
Optimising outcome on thiopuri ...... o-prescription of allopurinol.
@nl
type
label
Optimising outcome on thiopuri ...... o-prescription of allopurinol.
@en
Optimising outcome on thiopuri ...... o-prescription of allopurinol.
@nl
prefLabel
Optimising outcome on thiopuri ...... o-prescription of allopurinol.
@en
Optimising outcome on thiopuri ...... o-prescription of allopurinol.
@nl
P2093
P1476
Optimising outcome on thiopuri ...... o-prescription of allopurinol.
@en
P2093
Anthony M Marinaki
Jeremy D Sanderson
Melissa A Smith
Paul Blaker
Peter M Irving
Simon H Anderson
P304
P356
10.1016/J.CROHNS.2012.02.007
P577
2012-03-03T00:00:00Z